209467-52-7
Chemical Structure
Ceftobiprole
Synonym(s): Ro 63-9141; BAL 9141
- CAS No.: 209467-52-7
- Formula:C20H22N8O6S2
- Molecular Weight:534.57
IUPAC Name: (6R,7R)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetamido)-8-oxo-3-((E)-((R)-2-oxo-[1,3'-bipyrrolidin]-3-ylidene)methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
InChIKey: VOAZJEPQLGBXGO-SDAWRPRTSA-N
SMILES: O=C(C(N12)=C(/C=C3C(N([C@H]4CNCC4)CC/3)=O)CS[C@]2([H])[C@H](NC(/C(C5=NSC(N)=N5)=N\O)=O)C1=O)O
Biological Activity: Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci with a MIC90 value of 2 μg/mL for MRSA. Ceftobiprole also inhibits gram-positive and gram-negative pathogens. Ceftobiprole can be used for the study of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ceftobiprole | 97.22% | Ceftobiprole (Ro 63-9141) is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci with a MIC90 value of 2 μg/mL for MRSA. Ceftobiprole also inhibits gram-positive and gram-negative pathogens. Ceftobiprole can be used for the study of hospital-acquired pneumonia (excluding ventilator-associated pneumonia) and community-acquired pneumonia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kisgen J, et al. Ceftobiprole, a Broad-Spectrum Cephalosporin With Activity against Methicillin-Resistant Staphylococcus aureus (MRSA). P T. 2008 Nov;33(11):631-41. [Content Brief]
- [2]. Hodille E, et al. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections. Med Mal Infect. 2017 Mar;47(2):152-157. [Content Brief]
- [3]. E Azoulay-Dupuis, et al. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia. Antimicrob Agents Chemother. 2004 Apr;48(4):1105-11. [Content Brief]
